{"id":259,"date":"2018-01-22T03:23:46","date_gmt":"2018-01-22T03:23:46","guid":{"rendered":"http:\/\/www.cscr.in\/symposium\/?page_id=259"},"modified":"2019-01-07T04:27:16","modified_gmt":"2019-01-07T04:27:16","slug":"cgts-2017","status":"publish","type":"page","link":"https:\/\/www.cscr.res.in\/symposium\/index.php\/cgts-2017\/","title":{"rendered":"CGTS 2017"},"content":{"rendered":"

2nd<\/sup> Annual Cell and Gene Therapy Symposium<\/strong><\/span><\/p>\n

7-8 September, 2017<\/strong><\/span><\/p>\n

Scientific Program<\/h3>\n

DAY-1: THURSDAY, 07TH<\/sup> SEPTEMBER, 20<\/span>17<\/strong>
\n<\/strong><\/h4>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
12:45 to 1:00pm<\/p>\n

1:00 to 1:10PM<\/p>\n

1:10 to 1:20PM<\/p>\n

\u00a0<\/strong><\/td>\n

Welcome and introductory remarks \u2013 Director \/ Principal, CMC, Vellore<\/strong><\/p>\n

Address by Dr. K. VijayRaghavan<\/strong>, Secretary, Department of Biotechnology (DBT), Govt. of India<\/p>\n

Address by Dr. Soumya Swaminathan<\/strong>, Secretary, Department of Health Research (DHR), Govt. of India & Director General, Indian Council of Medical Research (ICMR)<\/td>\n<\/tr>\n

Session-1: <\/em><\/strong>CELL & GENE THERAPY: BENCH TO BEDSIDE<\/strong><\/td>\n<\/tr>\n
Chair: <\/em><\/strong>Dr. Alok Srivastava<\/strong><\/td>\n<\/tr>\n
1:25 to 1:30PM<\/td>\nIntroduction to the session<\/td>\n<\/tr>\n
1:30 to 2:00PM<\/td>\nGene modified cell therapies \u2013 Bench to bedside<\/td>\nDr. Trent Spencer<\/strong><\/p>\n

Emory University<\/p>\n

School of Medicine, USA<\/td>\n<\/tr>\n

2:00 to 2:30PM<\/td>\nGene therapy for hemoglobin disorders \u2013 From concept to the clinic<\/td>\nDr. Mark Walters<\/strong><\/p>\n

UCSF Benioff Children’s Hospital, USA<\/td>\n<\/tr>\n

2:30 to 3:00PM<\/td>\nDeveloping cell therapies in India \u2013 Establishing the regulatory path<\/td>\nDr. Rajiv Sarin<\/strong><\/p>\n

Cancer Genetics Unit, Tata Memorial Centre & Chairman, NAC-SCRT, India<\/td>\n<\/tr>\n

Session-2: <\/em><\/strong>\u00a0CELL THERAPY<\/strong><\/td>\n<\/tr>\n
Chair: <\/em><\/strong>Dr. Velu Nair<\/strong><\/td>\n<\/tr>\n
3:00 to 3:05PM<\/td>\nIntroduction to the session<\/td>\n<\/tr>\n
3:05 to 3:35PM<\/td>\nEngineering gamma delta T cell therapy for cancer \u2013<\/p>\n

Standardizing production & IND enabling preclinical studies<\/td>\n

Dr. Trent Spencer<\/strong><\/p>\n

Emory University<\/p>\n

School of Medicine, USA<\/td>\n<\/tr>\n

3:35 to 4:05PM<\/td>\nGamma delta T cell based Cancer Immunotherapy: Basic Biology to Clinical Application<\/td>\nDr. Shubhada Chiplunkar<\/strong><\/p>\n

Advanced Centre for Treatment, Research and Education in Cancer, India<\/td>\n<\/tr>\n

4:05 to 4:35PM<\/td>\nHaplobanking in India \u2013 Preparing for universal cell therapy<\/td>\nDr. R. V. Shaji<\/strong><\/p>\n

Centre for Stem Cell Research, India<\/td>\n<\/tr>\n

4:35 to 5:00PM<\/td>\n\n

Tea Break<\/em><\/strong><\/p>\n<\/td>\n<\/tr>\n

Session-3: <\/em><\/strong>GENE THERAPY FOR HEMOGLOBIN DISORDERS<\/strong><\/td>\n<\/tr>\n
Chair: <\/em><\/strong>Dr. Mammen Chandy<\/strong><\/td>\n<\/tr>\n
5:00 to 5:05PM<\/td>\nIntroduction to the session<\/td>\n<\/tr>\n
5:05 to 5:35PM<\/td>\nLentiviral vector based gene therapy for beta thalassemia major and sickle cell disease<\/td>\nDr. Mark Walters<\/strong><\/p>\n

UCSF Benioff Children’s Hospital, USA<\/td>\n<\/tr>\n

5:35 to 6:05PM<\/td>\nGene therapy of human hemoglobinopathies with AAV vectors<\/td>\nDr. Arun Srivastava<\/strong><\/p>\n

University of Florida<\/p>\n

College of Medicine, USA<\/td>\n<\/tr>\n

6:05 to 6:35PM<\/td>\nGene therapy for haemoglobinopathies: The French experience<\/td>\nDr. Elisa Magrin<\/strong><\/p>\n

Cell and Gene Therapy Lab, Necker Hospital, France<\/td>\n<\/tr>\n

6:35 to 7:05PM<\/td>\nDeveloping gene therapy for haemoglobin disorders in India<\/td>\nDr. Mohankumar Murugesan<\/strong><\/p>\n

Centre for Stem Cell Research, India<\/td>\n<\/tr>\n

Key note lecture<\/em>: <\/strong>EVOLUTION OF GENE THERAPY<\/strong><\/td>\n<\/tr>\n
Chair: <\/em><\/strong>Dr. Alok Srivastava<\/strong><\/td>\n<\/tr>\n
7:05 to 7:10PM<\/td>\nIntroduction<\/td>\n<\/tr>\n
7:10 to 8:00PM<\/td>\nAAV: From Almost A Virus to An Awesome Vector<\/td>\nDr. Arun Srivastava<\/strong><\/p>\n

University of Florida<\/p>\n

College of Medicine, USA<\/td>\n<\/tr>\n

8:00PM onwards<\/td>\n\n

Dinner<\/em><\/strong><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u00a0<\/strong><\/p>\n

DAY-2: FRIDAY, 08TH<\/sup> SEPTEMBER, 2017<\/strong><\/span><\/h4>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Session-4: <\/em><\/strong>CANCER CELL AND GENE THERAPY<\/strong><\/td>\n<\/tr>\n
Chair: <\/em><\/strong>Dr. Rita Mulherkar<\/strong><\/td>\n<\/tr>\n
8:30 to 8:35AM<\/td>\nIntroduction to the session<\/td>\n<\/tr>\n
8:35 to 9:05AM<\/td>\nCombating cancer through targeted chemotherapy in combination with in vivo dendritic cell targeted genetic immunization<\/td>\nDr. Arabinda Chaudhuri<\/strong><\/p>\n

CSIR-Indian Institute of Chemical Technology, India<\/td>\n<\/tr>\n

9:05 to 9:35AM<\/td>\nDendritic cell vaccine for cervical cancer<\/td>\nDr. Thangarajan Rajkumar<\/strong><\/p>\n

Adyar Cancer Institute, India<\/td>\n<\/tr>\n

9:35 to 10:00AM<\/td>\n\n

Tea Break<\/em><\/strong><\/p>\n<\/td>\n<\/tr>\n

Session-5:<\/em><\/strong> NON-VIRAL GENE TRANSFER TECHNOLOGY<\/strong><\/td>\n<\/tr>\n
Chair: <\/em><\/strong>Dr. Rajiv Sarin<\/strong><\/td>\n<\/tr>\n
10:00 to 10:05AM<\/td>\nIntroduction to the session<\/td>\n<\/tr>\n
10:05 to 10:35AM<\/td>\nsiRNA for therapeutic gene regulation<\/td>\nDr. Narendra Chirmule<\/strong><\/p>\n

Biocon Research Limited, India<\/td>\n<\/tr>\n

10:35 to 11:05AM<\/td>\nGlucocorticoid receptor: A potent cell & gene therapy target for cancer and cancer stem cells<\/td>\nDr. Rajkumar Banerjee<\/strong><\/p>\n

CSIR-Indian Institute of Chemical Technology, India<\/td>\n<\/tr>\n

11:05 to 11:35AM<\/td>\nTherapeutic Antisense Oligonucleotides based Exon Skipping Gene Editing Strategies in Duchenne Muscular Dystrophy<\/td>\nDr. Aravind Sankaramoorthy<\/strong><\/p>\n

Dystrophy Annihilation Research Trust, India<\/td>\n<\/tr>\n

11:35 to 12:05PM<\/td>\nImproving safety and efficacy of cationic nanocarrier enabled CRISPR\/Cas9 based genome editing<\/td>\nDr. Srujan Kumar Marepally<\/strong><\/p>\n

Centre for Stem Cell Research, India<\/td>\n<\/tr>\n

12:05 to 1:05PM<\/td>\n\n

Lunch<\/em><\/strong><\/p>\n<\/td>\n<\/tr>\n

Session-6:<\/em><\/strong> GENE EDITING TECHNOLOGY<\/strong><\/td>\n<\/tr>\n
Chair: <\/em><\/strong>Dr. R. V. Shaji<\/strong><\/td>\n<\/tr>\n
1:05 to 1:10PM<\/td>\nIntroduction to the session<\/td>\n<\/tr>\n
1:10 to 1:40PM<\/td>\nExpanding the genome editing toolbox<\/td>\nDr. Debojyoti Chakraborty<\/strong><\/p>\n

CSIR-Institute of Genomics and Integrative Biology, India<\/td>\n<\/tr>\n

1:40 to 2:10PM<\/td>\nCRISPR\/Cas9 gene editing to correct the sickle mutation<\/td>\nDr. David Martin<\/strong><\/p>\n

Children’s Hospital Oakland Research Institute, USA<\/td>\n<\/tr>\n

2:10 to 2:40PM<\/td>\nReactivation of fetal haemoglobin using targeted genome engineering approach<\/td>\nDr. Sivaprakash Ramalingam<\/strong><\/p>\n

CSIR-Institute of Genomics and Integrative Biology, India<\/td>\n<\/tr>\n

2:40 to 3:10PM<\/td>\nGenome editing for the gene therapy of Wiskott-Aldrich Syndrome<\/td>\nDr. Saravanabhavan Thangavel<\/strong><\/p>\n

Centre for Stem Cell Research, India<\/td>\n<\/tr>\n

3:10 to 3:15PM<\/td>\n\n

Conclusion remarks<\/strong><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Gallery<\/h3>\n

[soliloquy id=”312″]<\/p>\n

Abstracts<\/h3>\n